ATE359824T1 - Wässrige formulierung enthaltend menschliches wachstumshormon - Google Patents

Wässrige formulierung enthaltend menschliches wachstumshormon

Info

Publication number
ATE359824T1
ATE359824T1 AT99107148T AT99107148T ATE359824T1 AT E359824 T1 ATE359824 T1 AT E359824T1 AT 99107148 T AT99107148 T AT 99107148T AT 99107148 T AT99107148 T AT 99107148T AT E359824 T1 ATE359824 T1 AT E359824T1
Authority
AT
Austria
Prior art keywords
growth hormone
formulation containing
human growth
aqueous formulation
containing human
Prior art date
Application number
AT99107148T
Other languages
English (en)
Inventor
Connor Barbara H O
Eswein James O
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25448638&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE359824(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE359824T1 publication Critical patent/ATE359824T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT99107148T 1992-07-31 1993-07-29 Wässrige formulierung enthaltend menschliches wachstumshormon ATE359824T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92340192A 1992-07-31 1992-07-31

Publications (1)

Publication Number Publication Date
ATE359824T1 true ATE359824T1 (de) 2007-05-15

Family

ID=25448638

Family Applications (2)

Application Number Title Priority Date Filing Date
AT93918499T ATE197405T1 (de) 1992-07-31 1993-07-29 Wässrige arzneizusammensetzung, welche das menschliche wachstumshormon enthält
AT99107148T ATE359824T1 (de) 1992-07-31 1993-07-29 Wässrige formulierung enthaltend menschliches wachstumshormon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT93918499T ATE197405T1 (de) 1992-07-31 1993-07-29 Wässrige arzneizusammensetzung, welche das menschliche wachstumshormon enthält

Country Status (15)

Country Link
EP (2) EP0652766B2 (de)
JP (2) JP4018133B2 (de)
AT (2) ATE197405T1 (de)
AU (1) AU686567C (de)
CA (3) CA2337745C (de)
DE (2) DE69329651T3 (de)
DK (2) DK0652766T4 (de)
ES (2) ES2286868T3 (de)
GR (1) GR3035144T3 (de)
IL (1) IL106524A (de)
MD (1) MD1699F2 (de)
MX (1) MX9304613A (de)
NZ (1) NZ255158A (de)
PT (1) PT652766E (de)
WO (1) WO1994003198A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
DK0804223T3 (da) * 1994-06-17 2000-01-24 Applied Research Systems Farmaceutiske præparater indeholdende hGH
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
US6790439B1 (en) 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
SE9704405D0 (sv) * 1997-11-28 1997-11-28 Pharmacia & Upjohn Ab New syringe
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
JP4719357B2 (ja) * 1998-07-23 2011-07-06 アレス トレイディング ソシエテ アノニム Ｆｓｈ及びｆｓｈ変異体の製剤、製品及び方法
DE60038118T2 (de) * 1999-07-12 2009-03-05 Sandoz Ag Formulierungen von wachstumshormonen
EP2067488A1 (de) 2000-04-12 2009-06-10 Human Genome Sciences, Inc. Albuminfusionsproteine
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
JP2005538068A (ja) * 2002-07-09 2005-12-15 サンド・アクチエンゲゼルシヤフト 高濃度のヒト成長ホルモン（ｈＧＨ）とフェノールを含有する液剤
MXPA05007181A (es) 2002-12-31 2006-04-07 Altus Pharmaceuticals Inc Cristales de la hormona de crecimiento humano y metodos para prepararlos.
EA012565B1 (ru) 2003-04-02 2009-10-30 Арес Трейдинг С.А. Жидкие фармацевтические композиции фолликулостимулирующего гормона (фсг) и лютеинизирующего гормона (лг), содержащие неионогенное поверхностно-активное вещество
CA2526099C (en) 2003-06-20 2013-02-05 Ares Trading Sa Freeze-dried fsh / lh formulations
JP4845741B2 (ja) * 2003-12-23 2011-12-28 ファルマシア コーポレーション 安定な成長ホルモン液体製剤
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
DK1740213T3 (da) 2004-04-07 2012-04-10 Ares Trading Sa Væskeformulering til væksthormoner
US8334365B2 (en) 2006-06-07 2012-12-18 Human Genome Sciences, Inc. Albumin fusion proteins
LT2049148T (lt) * 2006-07-06 2016-11-25 Daewoong Co., Ltd. Žmogaus augimo hormono skysta stabili kompozicija
AU2007333959A1 (en) * 2006-12-18 2008-06-26 Altus Pharmaceuticals Inc. Human growth hormone formulations
WO2011000107A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
UA108994C2 (uk) * 2009-11-17 2015-07-10 Ипсен Фарма С.А.С. Фармацевтична композиція, що містить комбінацію hgh і rhigf-1, і процес її приготування (варіанти)
AU2011208620B2 (en) 2010-01-22 2015-04-16 Novo Nordisk Health Care Ag Stable growth hormone compounds
AU2011208625C1 (en) 2010-01-22 2022-08-18 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
WO2013014196A1 (en) * 2011-07-25 2013-01-31 Sandoz Ag Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein
US10064951B2 (en) * 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
JP5487276B2 (ja) * 2012-11-12 2014-05-07 デウン カンパニー，リミテッド ヒト成長ホルモンを含有する安定した液状製剤
WO2014166836A1 (en) * 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
CN113425835B (zh) * 2020-03-23 2024-03-19 常州健益生物制药有限公司 一种生长激素原料药溶液、水针剂及其制备方法
CN112494638B (zh) * 2020-12-22 2023-12-19 深圳科兴药业有限公司 一种人生长激素注射剂组合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
PT83095B (en) * 1985-07-30 1987-12-23 Int Minerals & Chem Corp Method for the stabilization of growth promoting hormones using polyoxyethylene-polyoxypropylene copolymers
ATE82506T1 (de) * 1987-08-21 1992-12-15 Imcera Group Inc Stabilisierung von wachstumshormonen.
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US4904043A (en) * 1988-06-15 1990-02-27 American Telephone And Telegraph Company, At&T Bell Laboratories Optical data link dual wavelength coupler
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method

Also Published As

Publication number Publication date
CA2139358A1 (en) 1994-02-17
DK0955062T3 (da) 2007-09-17
DE69329651T3 (de) 2008-10-30
EP0955062A1 (de) 1999-11-10
EP0652766B1 (de) 2000-11-08
WO1994003198A1 (en) 1994-02-17
AU4792793A (en) 1994-03-03
MD960246A (en) 1998-01-31
ES2153385T3 (es) 2001-03-01
CA2139358C (en) 2001-02-13
JP2007045841A (ja) 2007-02-22
DE69329651T2 (de) 2001-05-23
DK0652766T3 (da) 2001-01-29
AU686567B2 (en) 1998-02-12
AU686567C (en) 2002-08-08
ES2286868T3 (es) 2007-12-01
PT652766E (pt) 2001-04-30
IL106524A0 (en) 1993-11-15
EP0955062B1 (de) 2007-04-18
IL106524A (en) 2000-08-31
JP4018133B2 (ja) 2007-12-05
CA2489978A1 (en) 1994-02-17
JPH07509719A (ja) 1995-10-26
DE69329651D1 (de) 2000-12-14
MX9304613A (es) 1994-03-31
ATE197405T1 (de) 2000-11-11
CA2337745C (en) 2005-04-12
DE69334134D1 (de) 2007-05-31
MD1699F2 (ro) 2001-07-31
EP0652766B2 (de) 2008-03-19
CA2337745A1 (en) 1994-02-17
EP0652766A1 (de) 1995-05-17
GR3035144T3 (en) 2001-04-30
DE69334134T2 (de) 2007-12-20
NZ255158A (en) 1997-09-22
ES2153385T5 (es) 2008-09-01
DK0652766T4 (da) 2008-06-09

Similar Documents

Publication Publication Date Title
DE69334134D1 (de) Wässrige Formulierung enthaltend Menschliches Wachstumshormon
FI933393A0 (fi) Agglomererade hydrofila komplex med flerfasiga frigoeringsegenskaper
IL126463A0 (en) A pharmaceutical formulation containing growth hormone an amino acid and a non-ionic detergent
CZ307715A3 (cs) Způsob lyofilizace vodné farmaceutické formulace faktoru VIII prosté albuminu
ATE203411T1 (de) Lagerstabile wässrige pharmazeutische zubereitungen von g-csf
EP0497258A3 (en) Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer
MX9710206A (es) Composicion farmaceutica de amiodarone para administracion parenteral.
CA2226548A1 (en) Lyophilized hepatocyte growth factor preparations
GR3032546T3 (en) Use of azoles as virucidal agents in solutions of biologically active proteins
ES2138053T3 (es) Formulacion insecticida solida.
DK248987A (da) Farmaceutiske praeparater til forbedring af sammensaetningen af lipider i blod
KR950700743A (ko) 프로스타사이클린류를 활성성분으로서 함유하는 외용 피부치료제 조성물(dermatologic preparation composition containing prostacyclin as active ingredient)
SE8400971D0 (sv) Profylaktiskt och lekande medel for arterioskleros
GB2021581A (en) Stabilisation of PGl2 derivatives
EP0509098A4 (en) Ataractic
GR3018349T3 (en) Use of naproxen as mydriatic agent.
ITMI920760U1 (it) Struttura di utensile del tipo fresca o simile particolarmente per l'esecuzione di interventi chirurgici di implantollogia odontoiatrica
IT1255237B (it) Composizione farmaceuticaidrofila ad attivita' antiinfiammatoria
DK322187D0 (da) Azolderivater, fremgangsmaade til deres fremstilling og landbrugs- og havebrugsmidler indeholdende disse som aktiv bestanddel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0955062

Country of ref document: EP